LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVS

128.14

-0.44%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVS

128.14

-0.44%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVS

128.14

-0.44%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVS

128.14

-0.44%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVS

128.14

-0.44%↓

Search

Pulmatrix Inc

Slēgts

4.7 0.64

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.63

Max

4.74

Galvenie mērījumi

By Trading Economics

Ienākumi

259K

-1.5M

EPS

-0.42

Peļņas marža

-60,266.667

Darbinieki

2

EBITDA

260K

-1.5M

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-2.1M

18M

Iepriekšējā atvēršanas cena

4.06

Iepriekšējā slēgšanas cena

4.7

Pulmatrix Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 9. sept. 23:37 UTC

Karstas akcijas

Stocks to Watch: Oracle, Wearable Devices, GameStop

2025. g. 9. sept. 20:41 UTC

Peļņas

Oracle's Backlog Surges With Major Customer Deals in 1Q

2025. g. 9. sept. 20:30 UTC

Peļņas

GameStop 2Q Sales, Profit Rise

2025. g. 9. sept. 23:19 UTC

Tirgus saruna

ANZ Adds a Further 50 Bps in FOMC Cuts to Outlook -- Market Talk

2025. g. 9. sept. 21:35 UTC

Peļņas

Oracle Stock Soars on Strong AI Backlog. Earnings Were Good Enough. -- Barrons.com

2025. g. 9. sept. 21:32 UTC

Peļņas

Oracle's Backlog Swells With Big Customer Deals -- Update

2025. g. 9. sept. 21:02 UTC

Iegādes, apvienošanās, pārņemšana

DHL Adds to Healthcare Logistics Services With Acquisition -- Update

2025. g. 9. sept. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 9. sept. 20:33 UTC

Peļņas

These Stocks Moved the Most Today: Apple, UnitedHealth, Nebius, Wolfspeed, Tourmaline Bio, Albemarle, Dell, and More -- Barrons.com

2025. g. 9. sept. 20:26 UTC

Peļņas

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

2025. g. 9. sept. 20:23 UTC

Peļņas

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

2025. g. 9. sept. 20:12 UTC

Peļņas

Oracle Stock Jumps on Mixed Earnings Report -- Barrons.com

2025. g. 9. sept. 20:10 UTC

Peļņas

Oracle Expects Cloud Infrastructure Rev to Grow 77% to $18 B This Fiscal Yr >ORCL

2025. g. 9. sept. 20:10 UTC

Peļņas

Oracle Expects to Sign-Up Several Additional Multi-B-dollar Customers and RPO Is Likely to Exceed Half-A-Trillion Dollars Over Next Few Mos

2025. g. 9. sept. 20:09 UTC

Peļņas

Synopsys Sees 4Q Adj EPS $2.76-Adj EPS $2.80 >SNPS

2025. g. 9. sept. 20:09 UTC

Peļņas

Synopsys Sees 4Q Loss/Shr 16c-Loss 27c >SNPS

2025. g. 9. sept. 20:08 UTC

Peļņas

Oracle 1Q Short-term Deferred Rev Were $12.1 B >ORCL

2025. g. 9. sept. 20:08 UTC

Peļņas

Oracle 1Q Operating Income Was $4.3 B >ORCL

2025. g. 9. sept. 20:08 UTC

Peļņas

Oracle Expects MultiCloud Rev to Grow Substantially Every Qtr for Several Years >ORCL

2025. g. 9. sept. 20:08 UTC

Peļņas

Synopsys Sees 4Q Rev $2.23B-$2.26B >SNPS

2025. g. 9. sept. 20:07 UTC

Peļņas

Oracle Total Remaining Performance Obligations Up to $455 B >ORCL

2025. g. 9. sept. 20:06 UTC

Peļņas

Oracle 1Q Software Revenue $5.72B >ORCL

2025. g. 9. sept. 20:06 UTC

Peļņas

Synopsys 3Q Adj EPS $3.39 >SNPS

2025. g. 9. sept. 20:06 UTC

Peļņas

Oracle 1Q Cloud Revenue $7.19B >ORCL

2025. g. 9. sept. 20:05 UTC

Peļņas

Oracle 1Q Rev $14.93B >ORCL

2025. g. 9. sept. 20:05 UTC

Peļņas

Oracle 1Q EPS $1.01 >ORCL

2025. g. 9. sept. 20:05 UTC

Peļņas

Synopsys 3Q EPS $1.50 >SNPS

2025. g. 9. sept. 20:05 UTC

Peļņas

Oracle 1Q Services Revenue $1.35B >ORCL

2025. g. 9. sept. 20:05 UTC

Peļņas

Oracle 1Q Adj EPS $1.47 >ORCL

2025. g. 9. sept. 20:05 UTC

Peļņas

Oracle 1Q Hardware Revenue $670M >ORCL

Salīdzinājums

Cenas izmaiņa

Pulmatrix Inc Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

0

Pirkt

0

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Pulmatrix Inc

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.
help-icon Live chat